March 10, 2020

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model

Category: Article Summary

Topic: Testing and Treatment

• Fan et al repurposed clinically approved drugs for the treatment of COVID-19, reporting that cepharanthine (CEP), selamectin, and mefloquine hydrochloride exhibited complete inhibition of cytopathic effects in cell culture at 10 μmol/L and should be considered potential drugs for treating SARS-CoV-2 infection. Clinical trials are needed.

Fan et al. (Mar 6, 2020). Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Print downloaded Mar 10 from https://doi.org/10.1097/CM9.0000000000000797